Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability and PK of NPT520-34 in Healthy Subjects
NCT03954600Phase 1Completed
- Sponsor
- Neuropore Therapies, Inc.
- Start
- May 2019
- Primary completion
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of NPT520-34 in Parkinson's disease (PD) and amyotrophic lateral sclerosis (ALS) (8 arms), sponsored by Neuropore Therapies, Inc. Primary endpoints: Safety/Tolerability of Single Ascending Doses at Day 7, Maximum observed plasma concentration of Single Ascending Doses at Day 7 and 26 more. Started May 2019; status: completed.
02
Drugs
NPT520-34
03
Conditions
Parkinson's disease (PD)amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT03954600.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03954600.